紫杉醇注射液联合卡铂治疗卵巢癌对患者免疫功能的影响

摘要/Abstract

摘要： 目的探讨紫杉醇注射液联合卡铂治疗卵巢癌对患者免疫功能的影响。方法选取2019年1月—2023年1月新疆石河子市人民医院收治的70例卵巢癌患者作为研究对象,依照治疗方法将患者分为观察组（n=35）与对照组（n=35）。对照组在病理诊断确诊后住院应用卡铂进行治疗,观察组患者病理诊断确诊后住院应用紫杉醇注射液联合卡铂治疗。比较两组患者临床疗效、治疗前后肿瘤标志物血管生成因子表达水平变化,并比较两组患者治疗前后免疫功能变化。结果观察组客观缓解率与疾病控制率明显高于对照组,差异有统计学意义（P<0.05）;两组患者治疗前bFGF、VEGF血管生成因子,CA125、Cyfra21-1肿瘤标志物水平比较,差异无统计学意义（P>0.05）,治疗后两组患者bFGF、VEGF血管生成因子,CA125、Cyfra21-1肿瘤标志物水平均降低,且观察组低于对照组,差异有统计学意义（P<0.05）;治疗前两组患者CD4⁺、CD3⁺和CD4⁺/ CD8⁺数值比较,差异无统计学意义（P>0.05）,治疗后两组患者CD4⁺、CD3⁺和CD4⁺/CD8⁺数值均降低,且观察组高于对照组,差异有统计学意义（P<0.05）。结论紫杉醇注射液联合卡铂治疗卵巢癌疗效显著,能够抑制肿瘤进展,降低肿瘤标志物及血管生成因子表达水平,且能够减轻患者化疗过程中出现的免疫功能损伤,值得临床应用。

关键词: 紫杉醇, 卡铂, 卵巢癌, 免疫功能, 临床疗效, 肿瘤标志物

Abstract: Objective To investigate the effect of paclitaxel injection combined with carboplatin on immune function in patients with ovarian cancer. Methods 70 patients with ovarian cancer admitted to Shihezi People's Hospital of Xinjiang from January 2019 to January 2023 were retrospectively analyzed, according to treatment methods, the patients were divided into observation group (n=35) and control group (n=35). The control group was treated with carboplatin after confirmed pathological diagnosis and hospitalization, and the observation group was treated with paclitaxel injection combined with carboplatin after confirmed pathological diagnosis and hospitalization. The clinical efficacy, the expression level of tumor marker angiogenesis factor before and after treatment, and the immune function changes of the two groups were compared. Results The objective remission rate and disease control rate of the observation group were significantly higher than those of the control group (P<0.05); There was no significant difference in the levels of bFGF, VEGF angiogenic factor, CA125, and Cyfra21-1 tumor markers between the two groups of patients before treatment (P>0.05). After treatment, the levels of bFGF, VEGF angiogenic factor, CA125, and Cyfra21-1 tumor markers decreased in both groups of patients, and the observation group was lower than the control group (P<0.05); Before treatment, there was no significant difference in the CD4⁺, CD3⁺, and CD4⁺/CD8⁺values between the two groups of patients. After treatment, the CD4⁺, CD3⁺, and CD4⁺/CD8⁺ values of the two groups of patients decreased, and the observation group was higher than the control group (P<0.05). Conclusion The combination of paclitaxel injection and carboplatin has a significant therapeutic effect on ovarian cancer, which can inhibit tumor progression, reduce the expression levels of tumor markers and angiogenic factors, and alleviate immune function damage in patients during chemotherapy. It is worthy of clinical application and promotion.

Key words: paclitaxel, carboplatin, oophoroma, immunity, clinical efficacy, tumor markers

中图分类号:

喻霞, 齐慧丽, 张春红. 紫杉醇注射液联合卡铂治疗卵巢癌对患者免疫功能的影响[J]. 中华养生保健, 2024, 42(8): 40-44.

YU Xia, QI Hui-li, ZHANG Chun-hong. Effect of Paclitaxel Injection Combined with Carboplatin on Immune Function in Patients with Ovarian Cancer[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(8): 40-44.

参考文献

[1] CHEN J, WEI Z, FU K, et al.Non-apoptotic cell death in ovarian cancer: Treatment, resistance and prognosis[J]. Biomed Pharmacother,2022,150:112929.
[2] MILLER R E, LEARY A, SCOTT C L, et al.ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer[J]. Ann Oncol,2020,31(12):1606-1622.
[3] 孙红辉,吴清珍.紫杉醇、卡铂联合放疗对可切除食管腺癌患者临床疗效的影响分析[J].临床医学工程,2023,30(2):209-210.
[4] 贾宇,张茜,崔璨.紫杉醇联合卡铂方案在三阴性乳腺癌辅助化疗中的临床应用效果[J].临床研究,2023,31(3):22-25.
[5] 张小娜,符燕妹,田燕,等.老年妇科肿瘤患者紫杉醇联合卡铂化疗后CINV发生影响因素[J].中国老年学杂志,2023,43(6):1316-1319.
[6] 中国抗癌协会妇科肿瘤专业委员会.卵巢癌诊疗指南(2022年版)[J].国家卫生健康委办公厅,2022:3-5.
[7] REED N, MILLAN D, VERHEIJEN R, 等.欧洲肿瘤内科协会对非上皮性卵巢癌的诊断、治疗和随访所制定的临床实践指南[J].国际妇产科学杂志,2011,38(4):339-342.
[8] 蔡莹颖. 多西紫杉醇分别联合卡培他滨与卡铂治疗乳腺癌肺转移的疗效比较[J].临床合理用药杂志,2023,16(5):134-136.
[9] 罗小桐,董信春,苟云久,等.紫杉醇+卡铂联合与不联合贝伐珠单抗治疗晚期非小细胞肺癌临床效果的系统评价与Meta分析[J].中国胸心血管外科临床杂志,2023,30(1):126-132.
[10] 刘伟辉,周益臣,杨倩,等.白蛋白结合型紫杉醇联合卡铂化疗对中晚期非小细胞肺癌患者免疫功能及预后的影响[J].临床合理用药杂志,2023,16(12):69-71.
[11] 刘金玉,武小冬,陈孟莉.帕博利珠单抗联合白蛋白结合型紫杉醇及卡铂致严重视神经病变1例[J].医药导报,2023,42(5):764-766.
[12] 谭树芬,杨琳琳,何利平,等.紫杉醇联合卡铂化疗对卵巢癌凝血/纤溶及CA125/HE4水平的调控及临床意义[J].中国病理生理杂志,2023,39(3):503-509.
[13] 李芬芬,肖晓敏.化疗联合程序性死亡受体1抑制剂新辅助治疗局部晚期食管鳞状细胞癌的疗效[J].癌症进展,2023,21(1):66-70,74.
[14] 吴利琼,李雪,梅王梅.麦冬皂苷介导的IGF2信号对卵巢癌大鼠免疫功能的影响及相关机制研究[J].临床和实验医学杂志,2022,21(22):2353-2356.
[15] 王学博,符攀峰,任红娟,等.紫杉醇,顺铂方案联合腹腔热灌注化疗对晚期卵巢癌病人免疫功能及生存质量的影响[J].安徽医药,2022,26(4):791-795.
[16] 王俐力,丁国范,杨丽杰,等.不同剂型紫杉醇联合卡铂治疗晚期卵巢癌患者的临床疗效及对血清人附睾蛋白4,糖类抗原125和T淋巴细胞亚群水平的影响[J].癌症进展,2021,19(8):844-847,855.
[17] 刘小会,田露.卵巢癌患者D二聚体和中性粒细胞/淋巴细胞比值水平与预后的关系[J].血栓与止血学,2022,28(3):914-916.
[18] 仇玉兰,张玮,杨淑丽.紫杉醇联合卡铂新辅助化疗对局部晚期宫颈癌患者的疗效及其对免疫功能和远期预后的影响[J].中国性科学,2021,30(2):78-81.